February 08 was a positive day for ProMetic Life Sciences Inc. (PLI:CA) as its stock finished the day having gained 5.66% to hit a price of $0.28 a share. The company reached a market cap of 206.96 million and has 739.13 million shares outstanding. ProMetic Life Sciences Inc. is a component of the the S&P/TSX Composite Index.
978,910 shares changed hands over the course of the day as compared to an average volume of 1.45 million over the last 30 days for ProMetic Life Sciences Inc..
Prometic Life Sciences Inc is a global biopharmaceutical corporation supplying technologies for Bioseparations while also developing its own orphan drugs, plasma-derived therapeutics and small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. The company also offers drug purification of biologics, drug development, proteomics and the elimination of pathogens. The company’s segments consist of the Small molecule therapeutics segment, the Plasma-derived therapeutics segment and the Bioseparations segment. Majority of the revenue is derived from the Small molecule therapeutics segment that develops drug candidates for rare or orphan indications.. The company makes its home in Laval, QC, and is currently under the leadership of CEO Pierre Laurin.